How many 8-K filings has Shuttle Pharmaceuticals Holdings, Inc. filed?

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has 50 8-K (Current Event Report) filings on record, spanning Mar 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Shuttle Pharmaceuticals Holdings, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Shuttle Pharmaceuticals Holdings, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) — 8-K Filings

All 8-K filings from Shuttle Pharmaceuticals Holdings, Inc.. Browse 50 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (50)

Shuttle Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Dec 29, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on December 23, 2025. The company also reported on unregistered sales of equ
8-K Filing — Nov 28, 2025
Shuttle Pharmaceuticals Enters Material Agreement, Completes Acquisition — Nov 26, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on November 26, 2025, that it entered into a material definitive agreement. The company also reported the compl
Shuttle Pharmaceuticals Announces Agreement Changes and Exit Costs — Nov 21, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on November 20, 2025, the entry into a material definitive agreement and the termination of a material definiti
Shuttle Pharmaceuticals Faces Delisting Concerns — Nov 17, 2025 Risk: high
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on November 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The co
8-K Filing — Nov 7, 2025
Shuttle Pharmaceuticals Reports Material Agreement Changes — Oct 21, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on October 21, 2025, reporting events that occurred on October 15, 2025. The filing indicates both the entry
Shuttle Pharmaceuticals Files 8-K for Material Agreement — Sep 22, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on September 22, 2025, reporting a material definitive agreement entered into on September 15, 2025. The fil
Shuttle Pharmaceuticals Reports Director and Officer Changes — Sep 18, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on September 18, 2025, reporting changes effective September 12, 2025. The filing pertains to the departure
Shuttle Pharmaceuticals Files 8-K on Officer/Director Changes — Sep 17, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on September 17, 2025, reporting events as of September 11, 2025. The filing pertains to the departure of di
Shuttle Pharmaceuticals Files 8-K on Officer/Director Changes — Sep 8, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on September 8, 2025, reporting on the departure of directors or certain officers, the election of directors
Shuttle Pharmaceuticals Reports Leadership and Compensation Changes — Sep 5, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on August 31, 2025, reporting changes in its board of directors and certain officers, as well as updates to
Shuttle Pharma Appoints New CMO, Elects New Director — Jul 30, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on July 24, 2025, a series of significant corporate actions. These include the departure of Director Dr. Robert
Shuttle Pharmaceuticals Files 8-K on Equity Sales — Jun 25, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on June 20, 2025, related to unregistered sales of equity securities. The co
Shuttle Pharmaceuticals Reports Director/Officer Changes — May 28, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on May 28, 2025, reporting events as of May 21, 2025. The filing indicates changes related to the departure
Shuttle Pharmaceuticals Reports Director/Officer Changes & Shareholder Votes — May 15, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on May 15, 2025, reporting events as of May 9, 2025. The filing covers the departure of directors, election
Shuttle Pharmaceuticals Files 8-K — Apr 21, 2025 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on April 21, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not con
Shuttle Pharmaceuticals Files 8-K — Apr 10, 2025 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on April 10, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not con
Shuttle Pharmaceuticals Enters Material Definitive Agreement — Apr 4, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on April 3, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delawa
Shuttle Pharmaceuticals Files 8-K: Agreements, Personnel Changes — Mar 31, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on March 30, 2025, reporting the entry into a material definitive agreement, the departure of directors or c
Shuttle Pharmaceuticals Enters Material Definitive Agreement — Mar 25, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on March 21, 2025. The filing also includes financial statements and exhibit
Shuttle Pharmaceuticals Files 8-K, Faces Listing Concerns — Mar 13, 2025 Risk: high
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on March 13, 2025, reporting a material definitive agreement and a notice of delisting or failure to satisfy
Shuttle Pharmaceuticals Files 8-K: Director Changes & Compensation Updates — Mar 12, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on March 12, 2025, reporting on the departure of a director, election of a new director, and changes in offi
Shuttle Pharmaceuticals Files 8-K on Agreements and Personnel Changes — Feb 28, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on February 28, 2025, reporting on several key events. These include entering into a material definitive agr
Shuttle Pharmaceuticals Enters Material Definitive Agreement — Feb 27, 2025 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on February 26, 2025. The filing also includes financial statements and exhi
Shuttle Pharmaceuticals Enters Material Definitive Agreement — Jan 28, 2025 Risk: medium
On January 23, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the
Shuttle Pharmaceuticals Files 8-K — Jan 21, 2025 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on January 21, 2025, reporting other events and financial statements. The filing does not contain specific d
Shuttle Pharmaceuticals Files 8-K Amid Listing Concerns — Jan 7, 2025 Risk: high
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on January 7, 2025, reporting events as of December 31, 2024. The filing indicates a potential notice of del
Shuttle Pharmaceuticals Files 8-K with Material Agreement — Dec 19, 2024 Risk: medium
On December 16, 2024, Shuttle Pharmaceuticals Holdings, Inc. entered into a Material Definitive Agreement. The company also reported other events and filed fina
Shuttle Pharmaceuticals Files 8-K — Nov 26, 2024 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on November 26, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The fil
Shuttle Pharmaceuticals Announces Material Agreement — Nov 1, 2024 Risk: medium
On October 31, 2024, Shuttle Pharmaceuticals Holdings, Inc. announced a material definitive agreement related to its operations. The company also disclosed info
Shuttle Pharmaceuticals Files 8-K — Oct 29, 2024 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on October 29, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing
8-K Filing — Oct 28, 2024
Shuttle Pharmaceuticals Enters Material Agreement, Reports Equity Sales — Oct 25, 2024 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on October 21, 2024, the entry into a material definitive agreement. The company also reported on unregistered
Shuttle Pharmaceuticals Enters Material Agreement — Oct 17, 2024 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on October 14, 2024, that it entered into a material definitive agreement. The company also reported on unregis
Shuttle Pharmaceuticals Faces Nasdaq Listing Rule Violation — Sep 13, 2024 Risk: high
Shuttle Pharmaceuticals Holdings, Inc. received a notice on September 10, 2024, indicating it failed to meet a continued listing rule or standard for The Nasdaq
Shuttle Pharmaceuticals Enters Material Definitive Agreement — Sep 10, 2024 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on September 4, 2024. The filing does not disclose specific details of the a
Shuttle Pharmaceuticals to Acquire 03 Life Sciences — Aug 28, 2024 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on August 27, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests
Shuttle Pharmaceuticals Faces Delisting Notice — Aug 26, 2024 Risk: high
Shuttle Pharmaceuticals Holdings, Inc. received a notice on August 21, 2024, indicating it failed to meet a continued listing rule or standard, potentially lead
Shuttle Pharmaceuticals (SHPH) Lists on Nasdaq — Aug 14, 2024 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) announced on August 8, 2024, that its common stock is now trading on The Nasdaq Stock Market LLC under the symbol
Shuttle Pharmaceuticals Enters Material Agreement, Modifies Security Holder Rights — Aug 7, 2024 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on August 5, 2024, that it entered into a material definitive agreement. The company also reported material mod
Shuttle Pharmaceuticals Files 8-K on Shareholder Matters — Aug 1, 2024 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on August 1, 2024, reporting on matters submitted to a vote of security holders as of July 31, 2024. The fil
Shuttle Pharmaceuticals Restates Financials — Jul 16, 2024 Risk: high
Shuttle Pharmaceuticals Holdings, Inc. announced on July 10, 2024, that it will not rely on previously issued financial statements or related audit reports. Thi
Shuttle Pharmaceuticals Elects New Directors, Reports Other Events — Jun 18, 2024 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on June 13, 2024, a series of significant corporate actions. These include the election of two new directors, D
Shuttle Pharmaceuticals Files 8-K — May 22, 2024 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on May 22, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contai
Shuttle Pharmaceuticals Files 8-K on Financials — May 14, 2024 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing includes financi
Shuttle Pharma Collaborates with NCI on Cancer Therapies — Apr 29, 2024 Risk: medium
Shuttle Pharmaceuticals Holdings, Inc. announced on April 29, 2024, that it has entered into a strategic collaboration with the National Cancer Institute (NCI)
Shuttle Pharmaceuticals Files 8-K — Apr 23, 2024 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on April 23, 2024, reporting other events and financial statements. The filing does not contain specific det
Shuttle Pharmaceuticals Files 8-K on Financials — Mar 22, 2024 Risk: low
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on March 22, 2024, reporting on its results of operations and financial condition, as well as financial stat
Shuttle Pharmaceuticals Faces Delisting Concerns — Mar 5, 2024 Risk: high
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on March 5, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX